Loreena Hill

Loreena Hill

Auto-generated profile, based on publicly available information

Loreena Hill

School of Nursing and Paramedic Science, Ulster University , Belfast BT15 1AP, Northern Ireland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2017 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
UCUgo Corra
Ugo Corra
PAPiergiuseppe Agostoni
Piergiuseppe Agostoni
SAStefan D. Anker
Stefan D. Anker
ACAndrew J.S. Coats
Andrew J.S. Coats
MLMaria G. Crespo Leiro
Maria G. Crespo Leiro
MPMassimo F. Piepoli
Massimo F. Piepoli
Traditionally, the main indication for cardiopulmonary exercise testing (CPET) in heart failure (HF) was for the selection of candidates to heart transplantation: CPET was mainly performed in middle-aged male patients with HF and reduced left ventricular ejection fraction. Today, CPET is used in broader patients' populations, including women, elderly, patients with co-morbidities, those with preserved ejection fraction, or left ventricular assistance device recipients, i.e. individuals with different responses to incremental exercise and markedly different prognosis. Moreover, the diagnostic and prognostic utility of symptom-limited CPET parameters derived from submaximal tests is more and more considered, since many patients are unable to achieve maximal aerobic power. Repeated tests are also being used for risk stratification and evaluation of intervention, so that these data are now available. Finally, patients, physicians and healthcare decision makers are increasingly considering how treatments might impact morbidity and quality of life rather than focusing more exclusively on hard endpoints (such as mortality) as was often the case in the past. Innovative prognostic flowcharts, with CPET at their core, that help optimize risk stratification and the selection of management options in HF patients, have been developed.

6 September 2020 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
LHLoreena Hill
Loreena Hill
TGTal Prager Geller
Tal Prager Geller
RBResham Baruah
Resham Baruah
JBJames M. Beattie
James M. Beattie
JBJosiane Boyne
Josiane Boyne
TJTiny Jaarsma
Tiny Jaarsma
The Heart Failure Association of the European Society of Cardiology has published a previous position paper and various guidelines over the past decade recognizing the value of palliative care for those affected by this burdensome condition. Integrating palliative care into evidence-based heart failure management remains challenging for many professionals, as it includes the identification of palliative care needs, symptom control, adjustment of drug and device therapy, advance care planning, family and informal caregiver support, and trying to ensure a ‘good death’. This new position paper aims to provide day-to-day practical clinical guidance on these topics, supporting the coordinated provision of palliation strategies as goals of care fluctuate along the heart failure disease trajectory. The specific components of palliative care for symptom alleviation, spiritual and psychosocial support, and the appropriate modification of guideline-directed treatment protocols, including drug deprescription and device deactivation, are described for the chronic, crisis and terminal phases of heart failure.

22 April 2015 in European Journal of Cardiovascular Nursing
Verified
Journal Article
Open access
LHLoreena Hill
Loreena Hill
SMSonja McIlfatrick
Sonja McIlfatrick
BTBrian J Taylor
Brian J Taylor
LDLana Dixon
Lana Dixon
BCBen R Cole
Ben R Cole
DFDonna Fitzsimons
Donna Fitzsimons
The implantable cardioverter defibrillator (ICD) is a cornerstone in the treatment of life-threatening arrhythmias. As rates of device implantation continue to rise throughout Europe, European and International guidelines recommend professionals discuss deactivation with patients. In reality the appropriate therapeutic management of an ICD at the end-of-life remains uncertain in the minds of professionals and patients. To identify current practice and examine professional decision-making for patients with an ICD from time of implantation to final documentation and demise. Retrospective case note review of patients with an ICD who died during a 12 month period at a regional implantation centre. Fifty-nine patients were identified and medical notes of 44 of these patients were successfully retrieved. The majority of patients were male, mean age at time of death 73 years with one-third diagnosed with a malignancy prior to death. There was no documented evidence patients were informed about deactivation prior to ICD implantation. End-of-life management was discussed with 23 patients and on 17 occasions deactivation was included. Median time from discussion to death was seven days. In total 62.5% of patients who experienced a shock had an active ICD at death, while 93.7% who had their ICD deactivated never had a shock (p=0.003). Patients were not adequately informed regarding device deactivation prior to implantation, nor when their health deteriorated. The experience of a shock potentially affects professional decision making regarding device deactivation.

30 August 2024 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
PDF file
Mark SchuuringMark Schuuring
Mark Schuuring
RTRoderick Willem Treskes
Roderick Willem Treskes
TCTeresa Castiello
Teresa Castiello
MJMagnus Thorsten Jensen
Magnus Thorsten Jensen
RARuben Casado Arroyo
Ruben Casado Arroyo
LHLoreena Hill
Loreena Hill
The 2021 European Society of Cardiology guideline on diagnosis and treatment of acute and chronic heart failure (HF) and the 2023 Focused Update include recommendations on the pharmacotherapy for patients with New York Heart Association (NYHA) class II–IV HF with reduced ejection fraction. However, multinational data from the EVOLUTION HF study found substantial prescribing inertia of guideline-directed medical therapy (GDMT) in clinical practice. The cause was multifactorial and included limitations in organizational resources. Digital solutions like digital consultation, digital remote monitoring, digital interrogation of cardiac implantable electronic devices, clinical decision support systems, and multifaceted interventions are increasingly available worldwide. The objectives of this Clinical Consensus Statement are to provide (i) examples of digital solutions that can aid the optimization of prescription of GDMT, (ii) evidence-based insights on the optimization of prescription of GDMT using digital solutions, (iii) current evidence gaps and implementation barriers that limit the adoption of digital solutions in clinical practice, and (iv) critically discuss strategies to achieve equality of access, with reference to patient subgroups. Embracing digital solutions through the use of digital consults and digital remote monitoring will future-proof, for example alerts to clinicians, informing them of patients on suboptimal GDMT. Researchers should consider employing multifaceted digital solutions to optimize effectiveness and use study designs that fit the unique sociotechnical aspects of digital solutions. Artificial intelligence solutions can handle larger data sets and relieve medical professionals’ workloads, but as the data on the use of artificial intelligence in HF are limited, further investigation is warranted.

19 September 2014 in Palliative Medicine
Verified
Journal Article
Closed access
LHLoreena Hill
Loreena Hill
SMSonja McIlfatrick
Sonja McIlfatrick
BTBrian Taylor
Brian Taylor
LDLana Dixon
Lana Dixon
MHMark Harbinson
Mark Harbinson
DFDonna Fitzsimons
Donna Fitzsimons
Background: Individualised care at the end of life requires professional understanding of the patient’s perception of implantable cardioverter defibrillator deactivation. Aim: The aim was to evaluate the evidence on patients’ perception of implantable cardioverter defibrillator deactivation at end of life. Design: Systematic narrative review of empirical studies was published during 2008–2014. Data Sources: Data were collected from six databases, citations from relevant articles and expert recommendations. Results: In all, 18 studies included with collective population of n = 5810. Concept mapping highlighted three themes: (1) Diverse preferences regarding discussion and deactivation. Deactivation was rarely discussed pre-implantation, with some studies demonstrating patients’ reluctance to discuss implantable cardioverter defibrillator deactivation at any stage. Two studies found the majority of patients valued such discussions. Diversity was reflected in patients’ willingness to deactivate, ranging from 12% (n = 9) in Irish cohort to 79% (n = 195) in Dutch study. (2) Ethical and legal considerations were predominant in Canadian and American literature as patients wanted to contribute but felt the decision should be a doctor’s responsibility. Advance directives were uncommon in Europe, and where they existed the implantable cardioverter defibrillator was not mentioned. (3) ‘Living in the now’ was evident as despite deteriorating symptoms many patients maintained a positive outlook and anticipated surviving more than 10 years. Several studies asserted living longer was more important than quality of life. Conclusion: Patients regard the implantable cardioverter defibrillator as a complex and solely beneficial device, with little insight regarding its potential impact on a peaceful death. This review confirms the need for professionals to discuss with patients and families implantable cardioverter defibrillator functionality and deactivation at appropriate opportunities.

1 February 2021 in International Journal of Nursing Studies
Verified
Journal Article
Closed access
LCLorna Cassidy
Lorna Cassidy
LHLoreena Hill
Loreena Hill
DFDonna Fitzsimons
Donna Fitzsimons
JMJennifer McGaughey
Jennifer McGaughey